The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation (REDEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05902533
Recruitment Status : Recruiting
First Posted : June 15, 2023
Last Update Posted : February 23, 2024
Sponsor:
Information provided by (Responsible Party):
Jordan Kharofa, University of Cincinnati

Tracking Information
First Submitted Date  ICMJE June 5, 2023
First Posted Date  ICMJE June 15, 2023
Last Update Posted Date February 23, 2024
Actual Study Start Date  ICMJE August 14, 2023
Estimated Primary Completion Date August 14, 2026   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 5, 2023)
  • Assess Toxicity Index for all GI, GU, Dermatologic, and Hematologic CTCAE events from treatment initiation through 90 days post treatment [ Time Frame: 90 days post treatment ]
    Toxicity Index for all GI, GU, Dermatologic, and Hematologic CTCAE events from treatment initiation through 90 days post treatment. In patients treated with IMRT enrolled to NRG/RTOG 0529, the mean GI/GU/Derm/Hem TI was 3.858 (SD=0.892) assessed during this time period with standard nodal dose using a simultaneous integrated boost technique. Thirty-three patients will allow an effect size of 0.4 with 80% power and one-sided alpha of 0.05. This effect size is larger than the difference in toxicity observed compared to the historic standard of 3D-conformal radiation with IMRT (current standard) and thus felt to represent a clinically meaningful difference. The CTCAE Toxicity index will be determined for all Dermatologic, Gastrointestinal, Genitourinary, and hematologic events within 90 days from treatment initiation that are possible, probably, or definitely attributable to treatment.
  • Assess patient reported GI toxicity using PRO-CTCAE Diarrhea [ Time Frame: 9 weeks post treatment ]
    PRO-CTCAE Diarrhea will be used to assess patient reported GI toxicity for the primary endpoint at weeks 3, 5, and 9 (approximately 1-month post-treatment). Any high grade PRO-CTCAE Diarrhea (frequently/almost constantly) in week 3-9 was reported in 71% of patients on a prior trial in this population (UC-GI-1601) with standard nodal dose. With n=33 at alpha =0.05 (actual alpha=0.033) and power=0.80, we can detect a reduction in the proportion of patients reporting any PRO-CTCAE high grade diarrhea (week 3, 5, 9) of at least 22.3%.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 5, 2023)
  • Colostomy-Free-Survival - measured by follow up without colostomy [ Time Frame: 3 years (Patients followed 3 years post Treatment) ]
    Colostomy-Free-Survival - Time from treatment completion to any colostomy or last follow up without colostomy.
  • Disease Free Survival measured by digital rectal exam [ Time Frame: 3 and 6 months post treatment ]
    Disease Free Survival - Failure to achieve complete response (CR) at 6 months or subsequent recurrence. There will be a documented clinical response assessment of the primary anal tumor primarily by using digital rectal exam at 3 and 6 months to define clinical complete response along with a review of imaging at 6 months. Any residual tumor at 6 months would be considered "failure to achieve a complete response" and would be considered a DFS event. Resolution of the primary tumor after chemoradiation and recurrence of tumor (any size) would be considered a DFS event. Persistence of disease in grossly enlarged lymph node (GTV Gross Nodes) at 6 months or resolution and then recurrence (any size) would be considered DFS event. New lesions in the elective nodal space or any other location will be considered a DFS event.
  • Local Regional Recurrence [ Time Frame: 6 months post treatment ]
    Local Regional Recurrence - All failures within the PTVs for the primary tumor, for the involved Lymph Nodes, or for the Elective Lymph Nodes, including both patients who failed to achieve CR at 6 months and those occurring more than 6 months after completion of chemoradiation after initial CR.
  • Overall Survival - measured by survival or death at follow up [ Time Frame: 3 years (Patients followed 3 years post Treatment) ]
    Overall Survival - Time from registration to death or last follow up
  • Proportion of patients requiring a treatment break due to toxicity; measured by more than 3 consecutive fractions missed. [ Time Frame: Measured during the 5.5 - 6 week treatment period ]
    Treatment breaks- The proportion of patients requiring a treatment break due to toxicity (more than 3 consecutive fractions missed) will be monitored and reported. In RTOG 0529, 50% of patients treated with standard nodal dose required a treatment break.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
Official Title  ICMJE REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
Brief Summary To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
Detailed Description This is a multi-center, single arm prospective trial to evaluate whether reduced elective nodal dose (30.6 Gy) reduces toxicity as defined by the CTCAE Toxicity Index compared to historic patients treated with standard nodal dose on NRG/RTOG0529 and patient reported GI toxicity using the validated PRO-CTCAE scale for diarrhea compared to historic patients treated on UC-GI-1601.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Single arm prospective trial.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Anal Cancer
Intervention  ICMJE
  • Radiation: Radiation (reduced elective nodal dose (30.6 Gy)
    28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.
  • Drug: Capecitabine
    825 mg/m2 BID (Oral Twice daily on days with RT)
  • Drug: Mitomycin c
    10 mg/m2 slow IV push Day 1 and 29
Study Arms  ICMJE Experimental: Reduced Elective Dose + Concurrent Capecitabine/Mitomycin C
Reduced elective nodal dose (30.6 Gy); (28- 30 fractions given M-F for approximately 5.5 to 6 weeks) Capecitabine 825 mg/m2 BID on days with RT Mitomycin C 10 mg/m2 slow IV push Days 1 and 29
Interventions:
  • Radiation: Radiation (reduced elective nodal dose (30.6 Gy)
  • Drug: Capecitabine
  • Drug: Mitomycin c
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 5, 2023)
33
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 14, 2029
Estimated Primary Completion Date August 14, 2026   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age ≥18 years.
  2. Patients must have stage T1-4N+M0 or T3/T4N0M0 locally advanced anal cancer as evidenced by a PET scan AND either a CT with contrast of the abdomen/pelvis or an MRI with contrast of the pelvis. All imaging must be from within 60 days prior to registration.

    1. Note: Patients with T2N0 disease will be allowed if the primary tumor is >4 cm. Patients with Stage I-T1N0M0 or Stage II-T2N0M0 (tumor ≤ 4cm) will be ineligible for participation.
    2. Patients with perianal cancer that is HPV associated (P16+) will be eligible if the tumor extends to the anal verge and the CTV will include the mesorectal, internal/external iliac, and inguinal lymph nodes.
    3. Patients with excision of the primary tumor but with node positive disease or residual disease at the primary if T3T4N0 will be eligible.
  3. ECOG performance status 0 or 1 (or Karnofsky ≥70, see Appendix A).
  4. Patients must be able to receive concurrent treatment with capecitabine and Mitomycin C in the opinion of the investigator.
  5. Creatinine Clearance must be > 30 ml/min.
  6. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Any prior pelvic radiation.
  2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine.
  3. Patients with uncontrolled intercurrent illness that in the opinion of the investigator would prevent receipt of radiation or capecitabine.

    a. Note: HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

  4. Pregnant or breastfeeding women are excluded from this study.
  5. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen in the opinion of the investigator.
  6. Patients with active autoimmune or connective tissue disease requiring systemic treatment are excluded from this study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: UCCC Clinical Trials Office 513-584-7698 cancer@uchealth.com
Contact: Jordan Kharofa, MD kharofjr@ucmail.uc.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05902533
Other Study ID Numbers  ICMJE UCCC-GI-23-01
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Current Responsible Party Jordan Kharofa, University of Cincinnati
Original Responsible Party Same as current
Current Study Sponsor  ICMJE University of Cincinnati
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account University of Cincinnati
Verification Date February 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP